Daniel O'Connell
2021
In 2021, Daniel O'Connell earned a total compensation of $1.5M as President and Chief Executive Officer at Acumen Pharmaceuticals, a 340% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $275,422 |
|---|---|
| Option Awards | $676,217 |
| Salary | $524,597 |
| Other | $1,600 |
| Total | $1,477,836 |
O'Connell received $676.2K in option awards, accounting for 46% of the total pay in 2021.
O'Connell also received $275.4K in non-equity incentive plan, $524.6K in salary and $1.6K in other compensation.
Rankings
In 2021, Daniel O'Connell's compensation ranked 7,312th out of 12,406 executives tracked by ExecPay. In other words, O'Connell earned more than 41.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,312 out of 12,406 | 41st |
Division Manufacturing | 3,206 out of 5,492 | 42nd |
Major group Chemicals And Allied Products | 1,421 out of 2,368 | 40th |
Industry group Drugs | 1,265 out of 2,089 | 39th |
Industry Biological Products, Except Diagnostic Substances | 293 out of 452 | 35th |
Source: SEC filing on April 27, 2022.
O'Connell's colleagues
We found two more compensation records of executives who worked with Daniel O'Connell at Acumen Pharmaceuticals in 2021.